Dystonia management across Europe within ERN-RND: current state and future challenges

Background Since the first European-wide evaluation of dystonia management in 2016, several efforts have been made to improve dystonia-care. One of these was the development of the Dystonia Disease Group as a part of the European Reference Network for Rare Neurological Diseases (ERN-RND) that implemented several initiatives based on the recommendations made in 2016. Aim To evaluate the current state of dystonia management across Europe. Methods Twenty-four countries were surveyed via 62 dystonia-experts from 44 ERN-RND-related centers. Results Dystonia-experts for adult patients were available in all surveyed countries. However, almost half of the countries evaluated accessibility as merely 'satisfactory'. Access to genetic and neurophysiological testing was challenging to varying degrees in over half of countries. Main oral medications and botulinum toxin were available in all countries. Deep brain stimulation (DBS) was easily accessible in one-third of the countries. Dystonia research was conducted in 20/24 countries. Trainings on dystonia for general practitioners (GPs) were available in 11/24 countries. However, lack of trainings for other professionals was almost general. For pediatric dystonia, experts and specific training were available in over half of the countries. Conclusions In this overview, we present the current state of dystonia management within ERN-RND. Management has slightly improved since 2016 in several fields, including diagnostics, availability of DBS, and research. The results highlight that future challenges in dystonia management are accessibility of experts, and diagnostic tools and treatments, education on adult and childhood dystonia, and optimization of referral pathways. These findings are important for improving dystonia care across Europe.

Automated summary

This study evaluated the current state of dystonia management in Europe and found that accessibility was only considered "satisfactory" in nearly half of the surveyed countries, with over half of the countries facing challenging access to genetic and neurophysiological testing. Main oral medications and botulinum toxin were available in all countries, but deep brain stimulation (DBS) was easily accessible in only one-third of the countries. For pediatric dystonia, over half of the countries had experts and specific training available.